#1 Clinical Trials Search in Europe

Wt1 Lamp Mrna Dc

Clinical trials are currently underway to investigate the potential of WT1 LAMP mRNA DC, a novel immunotherapy vaccine, in treating various types of cancer. These trials aim to evaluate the safety, feasibility, and effectiveness of this treatment when combined with standard therapies for conditions such as glioblastoma, malignant pleural mesothelioma, and pediatric high-grade gliomas. The studies focus on using dendritic cells loaded with Wilms’ Tumor 1 (WT1) mRNA to stimulate the immune system against cancer cells.

Table of Contents

What is WT1 LAMP mRNA DC?

WT1 LAMP mRNA DC is an innovative immunotherapy treatment being studied for various types of cancer. It is a type of dendritic cell vaccine that uses the patient’s own immune cells to fight cancer[1]. The name breaks down as follows:

  • WT1: Stands for Wilms’ Tumor 1, a protein found in many types of cancer cells
  • LAMP: Lysosome-Associated Membrane Protein, which helps the vaccine work more effectively
  • mRNA: Messenger RNA, which carries instructions for making the WT1 protein
  • DC: Dendritic Cells, a type of immune cell that helps activate the body’s cancer-fighting T cells

How Does It Work?

The WT1 LAMP mRNA DC vaccine works by stimulating the patient’s immune system to recognize and attack cancer cells. Here’s a simplified explanation of the process:

  1. Doctors collect some of the patient’s blood cells through a process called leukapheresis[2].
  2. In the laboratory, these cells are transformed into dendritic cells and loaded with mRNA that instructs them to produce the WT1 protein.
  3. The modified dendritic cells are then injected back into the patient.
  4. Once in the body, these cells present the WT1 protein to the immune system, teaching it to recognize and attack cancer cells that express this protein.

What Conditions Does It Treat?

WT1 LAMP mRNA DC is being studied for several types of cancer, including:

  • Glioblastoma: A type of aggressive brain cancer[1]
  • Malignant Pleural Mesothelioma: Cancer that affects the lining of the lungs[2]
  • High-Grade Glioma (HGG): Another type of brain cancer[3]
  • Diffuse Intrinsic Pontine Glioma (DIPG): A rare brain tumor that typically affects children[3]

How Is It Administered?

WT1 LAMP mRNA DC is administered as a suspension for injection, typically given intradermally (into the skin)[1]. The treatment is usually given in multiple doses over a period of time, often in combination with other cancer treatments like chemotherapy or radiation therapy.

Current Clinical Trials

Several clinical trials are currently underway to study the effectiveness and safety of WT1 LAMP mRNA DC in different cancer types:

  • A study for newly diagnosed glioblastoma patients, combining the vaccine with standard chemotherapy (temozolomide)[1]
  • A trial for malignant pleural mesothelioma, combining the vaccine with chemotherapy and another immunotherapy drug called atezolizumab[2]
  • A study for children with high-grade glioma and diffuse intrinsic pontine glioma[3]
  • A trial for malignant pleural mesothelioma as a first-line treatment combined with standard chemotherapy[4]

Potential Benefits

While research is still ongoing, WT1 LAMP mRNA DC shows promise in several areas:

  • It’s a personalized treatment, using the patient’s own immune cells
  • It may help improve survival rates and slow disease progression
  • It can be combined with other cancer treatments for potentially better results
  • It might have fewer side effects compared to traditional cancer treatments

Possible Side Effects

As with any medical treatment, WT1 LAMP mRNA DC may cause side effects. Based on the clinical trials, these may include:

  • Local reactions at the injection site, such as redness or swelling
  • Flu-like symptoms
  • Fatigue

However, the full range of potential side effects is still being studied in clinical trials[4].

Conclusion

WT1 LAMP mRNA DC represents an exciting development in cancer immunotherapy. While it’s still in the clinical trial phase, this personalized treatment approach offers hope for patients with difficult-to-treat cancers. As research continues, we may learn more about its effectiveness and potential applications in cancer treatment.

Aspect Details
Treatment WT1 LAMP mRNA DC vaccine (dendritic cell immunotherapy)
Administration Intradermal injection
Cancer Types Studied Glioblastoma, Malignant pleural mesothelioma, Pediatric high-grade gliomas
Trial Phases Phase I/II
Primary Objectives Assess safety, feasibility, and efficacy
Secondary Objectives Evaluate overall survival, progression-free survival, immune responses
Combination Therapies Often combined with standard treatments (e.g., chemotherapy, radiation)
Key Eligibility Criteria Specific cancer diagnosis, age requirements, adequate health status
Safety Monitoring Adverse event reporting, clinical laboratory tests

FAQ

  • What is WT1 LAMP mRNA DC? WT1 LAMP mRNA DC is a type of cancer vaccine made from a patient's own dendritic cells. These cells are loaded with genetic material (mRNA) that codes for the Wilms' Tumor 1 (WT1) protein, which is found in many cancer types. This vaccine aims to stimulate the immune system to recognize and attack cancer cells.
  • What types of cancer are being studied with this vaccine? The clinical trials are investigating the use of WT1 LAMP mRNA DC in several cancer types, including glioblastoma (a type of brain cancer), malignant pleural mesothelioma (a cancer affecting the lining of the lungs), and high-grade gliomas in children.
  • How is the vaccine administered? The WT1 LAMP mRNA DC vaccine is administered through intradermal injection, which means it is injected just beneath the skin. The treatment schedule varies depending on the specific trial, but it is often given in combination with other standard cancer treatments.
  • What are the main goals of these clinical trials? The primary goals of these trials are to assess the safety, feasibility, and effectiveness of the WT1 LAMP mRNA DC vaccine. Researchers are looking at factors such as overall survival, progression-free survival, immune responses, and quality of life in patients receiving this treatment.
  • Who is eligible to participate in these trials? Eligibility criteria vary between trials but generally include patients with specific cancer diagnoses, age requirements, and health status considerations. For example, some trials are for adults with newly diagnosed glioblastoma, while others focus on children with high-grade gliomas. Patients must meet all criteria and provide informed consent to participate.

Ongoing Clinical Trials on Wt1 Lamp Mrna Dc

  • Study on Adding Atezolizumab and WT1/DC Vaccine to Standard Treatment for Patients with Epithelioid Malignant Pleural Mesothelioma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of WT1 LAMP mRNA DC Immunotherapy for Children with High-Grade Glioma and Diffuse Intrinsic Pontine Glioma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study of WT1 LAMP mRNA DC Vaccine for Patients with Malignant Pleural Mesothelioma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on WT1 LAMP mRNA DC and Temozolomide for Patients with Newly Diagnosed Glioblastoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Dendritic cells: Immune cells that process and present antigens to other immune cells, helping to stimulate an immune response against specific targets like cancer cells.
  • WT1 (Wilms' Tumor 1): A protein found in many types of cancer cells that can be targeted by the immune system when presented properly.
  • mRNA: Messenger RNA, a type of genetic material that carries instructions for making proteins in cells.
  • Glioblastoma: An aggressive type of brain cancer that forms from glial cells (cells that support and protect nerve cells).
  • Malignant pleural mesothelioma: A cancer that affects the thin layer of tissue that covers the lungs and chest wall, often associated with asbestos exposure.
  • High-grade glioma: A fast-growing type of tumor that arises from glial cells in the brain or spinal cord.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • Intradermal injection: A method of delivering a substance just beneath the skin.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Leukapheresis: A laboratory procedure in which white blood cells are separated from a sample of blood, often used to collect cells for making personalized vaccines.

References

  1. http://clinicaltrials.eu/trial/study-on-wt1-lamp-mrna-dc-and-temozolomide-for-patients-with-newly-diagnosed-glioblastoma/
  2. http://clinicaltrials.eu/trial/study-on-adding-atezolizumab-and-wt1-dc-vaccine-to-standard-treatment-for-patients-with-epithelioid-malignant-pleural-mesothelioma/
  3. http://clinicaltrials.eu/trial/study-of-wt1-lamp-mrna-dc-immunotherapy-for-children-with-high-grade-glioma-and-diffuse-intrinsic-pontine-glioma/
  4. http://clinicaltrials.eu/trial/study-of-wt1-lamp-mrna-dc-vaccine-for-patients-with-malignant-pleural-mesothelioma/